Keratoconus Treatment Market Introduction
Keratoconus is considered to be a progressive eye disorder in which the cornea, which is normally round in shape, thins, and starts bulging into a cone-like shape. This cone shape causes the light entering the eye to deflect on its way to the light-sensitive retina, thereby resulting into distorted vision. Weakening of corneal tissue which results into keratoconus can be because of enzymes imbalance within the cornea. This imbalance results in making the cornea more susceptible to oxidative damage from compounds known as free radicals, which causes it to weaken and bulge forward. Keratoconus also is related to overexposure to the sun’s ultraviolet rays, excessive rubbing of eyes, a history of contact lenses which are poorly fitted, and chronic eye irritation. Treatment for keratoconus disorder depends on the severity of condition and how rapidly the progression of the condition takes place. Mild to moderate keratoconus can be treated with contact lenses or eyeglasses. In some people suffering with keratoconus, wearing contact lenses becomes difficult or cornea becomes scarred. In these cases, surgery might be necessary.
Global Keratoconus Treatment Market: Competitive Landscape
Major players operating in the keratoconus treatment market are investing in R&D to develop effective solutions for keratoconus. Furthermore, rise in a number of approvals by the FDA for various new drugs and treatments for keratoconus, bolsters the growth of the keratoconus treatment market. For instance, in February 2019, Bausch + Lomb received 510(k) clearance for use of the Tangible Hydra-PEG Custom Contact Lens Coating Technology on several of its Boston Gas Permeable Lens Materials and Zenlens Family of Scleral Lenses. With this coating technology, eye care professionals have the opportunity to enhance contact lens customization for their patients using these Bausch + Lomb lens offerings.
In December 2016, Bausch + Lomb, a leading global eye health company, announced that its Specialty Vision Products business launched the Zenlens diagnostic lenses in a new 28 lens set format. Adding to the classic Zenlens 24 lens Dx format, which features six lenses in two diameters (16 mm and 17 mm) and two separate designs (prolate & oblate), the new 28 lens set adds four diagnostic lenses with toric peripheral curves.
Alcon
On June 29, 2018, Novartis announced its intention to seek shareholder approval for the spin-off of its Alcon Business, following the complete legal and structural separation of Alcon into a standalone company. Alcon has an array of eye care offerings in the industry with products organized into two businesses: Surgical and Vision Care. The vision care segment offers a broad range of daily disposable, reusable, and color-enhancing contact lenses; and a comprehensive portfolio of ocular health products. These include products for dry eye, contact lens care and ocular allergies, as well as ocular vitamins and redness relievers.
Bausch & Lomb Incorporated
Bausch + Lomb, a division of Bausch Health Companies Inc. is solely dedicated to protecting and enhancing the gift of sight for millions of people around the world. The company is one of the well-known and prestigious health care brands in the world. It offers a diverse and high quality range of eye health products, including contact lenses and lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company markets three broad categories of products: Vision Care, Pharmaceuticals, Cataract, and Vitreoretinal Surgery. Contact lens offerings under the vision care segment span the entire spectrum of wearing modalities. The cataract and vitreoretinal surgery segments offer a full suite of products including intraocular lenses and delivery systems. The pharmaceuticals segment offers products to treat a wide range of eye conditions including glaucoma, eye allergies, conjunctivitis, dry eye, and retinal diseases.
Other key players operating in the in the global keratoconus treatment market include CIBA VISION, CooperVision, HOYA VISION CARE, Menicon Co., Ltd., Johnson & Johnson Vision, SynergEyes Inc., Visionary Optics, and X-Cel Specialty Contacts. These players have adopted strategies such as agreements, partnerships, new product development, and collaborations to gain competitive advantage in the global keratoconus treatment market.
Global Keratoconus Treatment Market: Dynamics
Increase in Prevalence of Keratoconus
Increasing prevalence of the keratoconus disorder, is the reason responsible for boosting the keratoconus treatment market. According to National Keratoconus Foundation, in 2014, a study by American Journal of Ophthalmology found 218 newly diagnosed cases of keratoconus in the Netherlands. It determined the annual incidence (new cases) to be 1 in every 7,500 individuals.
Ultraviolet Radiations and Sun Exposure
According to a study titled “Epidemiology of Keratoconus Worldwide” by the Open Opthalmology Journal, ultraviolet radiation is regarded as one of the main causes for the development of keratoconus because of its oxidative damage. This can be illustrated by its high prevalence of keratoconus in hot and sunny areas. Higher prevalence of keratoconus has been identified in Saudi Arabia, Iran, New Zealand, Israel, and some Pacific Islands. One of the explanations for this can be high exposure to the sun and UV rays. Thus, ultraviolet radiations and sun exposure are likely to cause keratoconus disorder, thereby boosting the keratoconus treatment market.
Global Keratoconus Treatment Market: Segmentation
Based on type, the global keratoconus treatment market can be divided into:
In terms of diagnosis, the global keratoconus treatment market can be classified into:
Based on treatment, the global keratoconus treatment market can be categorized into:
In terms of end user, the global keratoconus treatment market can be divided into:
N/A
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Keratoconus Treatment Market
